The stock of Psyence Biomedical Ltd. (PBM) has seen a -20.60% decrease in the past week, with a -34.89% drop in the past month, and a -51.77% decrease in the past quarter. The volatility ratio for the week is 11.19%, and the volatility levels for the past 30 days are at 11.80% for PBM. The simple moving average for the past 20 days is -27.66% for PBM’s stock, with a -88.68% simple moving average for the past 200 days.
Is It Worth Investing in Psyence Biomedical Ltd. (NASDAQ: PBM) Right Now?
The 36-month beta value for PBM is also noteworthy at -0.36.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PBM is 7.42M, and at present, short sellers hold a 9.33% of that float. The average trading volume of PBM on September 04, 2024 was 2.42M shares.
PBM) stock’s latest price update
The stock of Psyence Biomedical Ltd. (NASDAQ: PBM) has decreased by -12.62 when compared to last closing price of 0.41.Despite this, the company has seen a loss of -20.60% in its stock price over the last five trading days. globenewswire.com reported 2024-08-30 that NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that the registration statement pertaining to its previously announced $25 million equity line of credit (the “ELOC”) with White Lion Capital, LLC, (“White Lion”) on Form F-1 has been declared effective by the U.S. Securities and Exchange Commission (SEC) on August 28, 2024. As previously disclosed, this 24-month arrangement allows Psyence Biomed to sell up to $25 million in shares to White Lion, subject to certain conditions.
PBM Trading at -18.95% from the 50-Day Moving Average
After a stumble in the market that brought PBM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.54% of loss for the given period.
Volatility was left at 11.80%, however, over the last 30 days, the volatility rate increased by 11.19%, as shares sank -30.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.18% lower at present.
During the last 5 trading sessions, PBM fell by -20.60%, in comparison to the 20-day moving average, which settled at $0.4871. In addition, Psyence Biomedical Ltd. saw -96.12% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PBM
The total capital return value is set at 0.53. Equity return is now at value 1.27, with 1.13 for asset returns.
Based on Psyence Biomedical Ltd. (PBM), the company’s capital structure generated -0.85 points at debt to capital in total, while cash flow to debt ratio is standing at -0.66.
Currently, EBITDA for the company is -2.75 million with net debt to EBITDA at -0.83. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.01.
Conclusion
In summary, Psyence Biomedical Ltd. (PBM) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
